Glanzmann's thrombasthenia epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{Glanzmann's thrombasthenia}} | {{Glanzmann's thrombasthenia}} | ||
{{CMG}} {AE}} {{OK}} [[User:Niush.D|Niyousha Danesh, MD-MPH]] | {{CMG}} {{AE}} {{OK}}, [[User:Niush.D|Niyousha Danesh, MD-MPH]] | ||
==Overview== | ==Overview== | ||
[[Glanzmann's thrombasthenia]] has [[incidence]]/[[prevalence]] of approximately one per 1,000,000 individuals worldwide. The highest reported [[prevalence]] in the world was in Iran, in 2004 the [[incidence]] of [[Glanzmann's thrombasthenia]] was approximately 2 per 100,000 individuals. [[Fatal]] [[bleeding]] can occur at any age in [[Glanzmann's thrombasthenia]] patients, however the [[prevalence]] of severe [[bleeding]] episodes are reduce with [[age]]. The [[case-fatality rate]] of [[Glanzmann's thrombasthenia]] is relatively low. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* | * [[Glanzmann's thrombasthenia]] has [[incidence]]/[[prevalence]] of approximately one per 1,000,000 individuals worldwide <ref name="pmid261854782">{{cite journal |vauthors=Solh T, Botsford A, Solh M |title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options |journal=J Blood Med |volume=6 |issue= |pages=219–27 |date=2015 |pmid=26185478 |pmc=4501245 |doi=10.2147/JBM.S71319 |url=}}</ref> | ||
* The highest reported [[prevalence]] in the world was in Iran, in 2004 the [[incidence]] of [[Glanzmann's thrombasthenia]] was approximately 2 per 100,000 individuals.<ref name="pmid15389911" /> | * The highest reported [[prevalence]] in the world was in Iran, in 2004 the [[incidence]] of [[Glanzmann's thrombasthenia]] was approximately 2 per 100,000 individuals.<ref name="pmid15389911" /> | ||
| Line 20: | Line 20: | ||
==== Race: ==== | ==== Race: ==== | ||
** [[Glanzmann's thrombasthenia]] usually affects individuals of the Arabs,Southern Indians,Hindus,Jordanians, Iranians,Palestinian, Iraqi Jews and French Gypsies races. individuals of the other parts of the world are less likely to develop [[Glanzmann's thrombasthenia]] <ref name="pmid2938617">{{cite journal |vauthors=Coller BS, Seligsohn U, Zivelin A, Zwang E, Lusky A, Modan M |title=Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection |journal=Br. J. Haematol. |volume=62 |issue=4 |pages=723–35 |date=April 1986 |pmid=2938617 |doi= |url=}}</ref><ref name="pmid12871468">{{cite journal |vauthors=Jacquelin B, Tuleja E, Kunicki TJ, Nurden P, Nurden AT |title=Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3 |journal=J. Thromb. Haemost. |volume=1 |issue=3 |pages=573–5 |date=March 2003 |pmid=12871468 |doi= |url=}}</ref> | ** [[Glanzmann's thrombasthenia]] usually affects individuals of the Arabs,Southern Indians,Hindus,Jordanians, Iranians,Palestinian, Iraqi Jews and French Gypsies races. individuals of the other parts of the world are less likely to develop [[Glanzmann's thrombasthenia]] <ref name="pmid2938617">{{cite journal |vauthors=Coller BS, Seligsohn U, Zivelin A, Zwang E, Lusky A, Modan M |title=Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection |journal=Br. J. Haematol. |volume=62 |issue=4 |pages=723–35 |date=April 1986 |pmid=2938617 |doi= |url=}}</ref><ref name="pmid12871468">{{cite journal |vauthors=Jacquelin B, Tuleja E, Kunicki TJ, Nurden P, Nurden AT |title=Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3 |journal=J. Thromb. Haemost. |volume=1 |issue=3 |pages=573–5 |date=March 2003 |pmid=12871468 |doi= |url=}}</ref> | ||
** | ** In Israel, 12 males and 10 females fulfilled the ‘Criteria for establishing the diagnosis of [[Glanzmann's thrombasthenia]] <ref name="pmid1239828">{{cite journal |vauthors=Reichert N, Seligsohn U, Ramot B |title=Clinical and genetic aspects of Glanzmann's thrombasthenia in Israel: report of 22 cases |journal=Thromb Diath Haemorrh |volume=34 |issue=3 |pages=806–20 |date=December 1975 |pmid=1239828 |doi= |url=}}</ref> | ||
** The majority of [[Glanzmann's thrombasthenia]] cases are reported in middle east including individuals of Palestinian, Israel Iran, Iraq, Saudi Arabia,India, Jordan and France. while in these [[ethnic group]]<nowiki/>s [[consanguineous]] marriages is more prevalent <ref name="pmid26185478">{{cite journal| author=Solh T, Botsford A, Solh M| title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. | journal=J Blood Med | year= 2015 | volume= 6 | issue= | pages= 219-27 | pmid=26185478 | doi=10.2147/JBM.S71319 | pmc=4501245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26185478 }}</ref> | |||
==== Sex ==== | ==== Sex ==== | ||
** Women are slightly more affected by [[Glanzmann's thrombasthenia]] than men. The female to male ratio is approximately 1.38 to 1. | ** Women are slightly more affected by [[Glanzmann's thrombasthenia]] than men. The female to male ratio is approximately 1.38 to 1. | ||
** | ** | ||
==References== | ==References== | ||
| Line 31: | Line 32: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 21:52, 29 July 2020
|
Glanzmann's thrombasthenia |
|
Differentiating Glanzmann's thrombasthenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glanzmann's thrombasthenia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Glanzmann's thrombasthenia epidemiology and demographics |
|
FDA on Glanzmann's thrombasthenia epidemiology and demographics |
|
CDC on Glanzmann's thrombasthenia epidemiology and demographics |
|
Glanzmann's thrombasthenia epidemiology and demographics in the news |
|
Blogs on Glanzmann's thrombasthenia epidemiology and demographics |
|
Risk calculators and risk factors for Glanzmann's thrombasthenia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2], Niyousha Danesh, MD-MPH
Overview
Glanzmann's thrombasthenia has incidence/prevalence of approximately one per 1,000,000 individuals worldwide. The highest reported prevalence in the world was in Iran, in 2004 the incidence of Glanzmann's thrombasthenia was approximately 2 per 100,000 individuals. Fatal bleeding can occur at any age in Glanzmann's thrombasthenia patients, however the prevalence of severe bleeding episodes are reduce with age. The case-fatality rate of Glanzmann's thrombasthenia is relatively low.
Epidemiology and Demographics
- Glanzmann's thrombasthenia has incidence/prevalence of approximately one per 1,000,000 individuals worldwide [1]
- The highest reported prevalence in the world was in Iran, in 2004 the incidence of Glanzmann's thrombasthenia was approximately 2 per 100,000 individuals.[2]
- Fatal bleeding can occur at any age in Glanzmann's thrombasthenia patients, however the prevalence of severe bleeding episodes are reduce with age.
- The case-fatality rate of Glanzmann's thrombasthenia is relatively low.
Age:
- The incidence of Glanzmann's thrombasthenia decreases with age; the median age at diagnosis is 8 years.[2]
- Glanzmann's thrombasthenia commonly manifests in individuals younger than 5 years of age.
Race:
- Glanzmann's thrombasthenia usually affects individuals of the Arabs,Southern Indians,Hindus,Jordanians, Iranians,Palestinian, Iraqi Jews and French Gypsies races. individuals of the other parts of the world are less likely to develop Glanzmann's thrombasthenia [3][4]
- In Israel, 12 males and 10 females fulfilled the ‘Criteria for establishing the diagnosis of Glanzmann's thrombasthenia [5]
- The majority of Glanzmann's thrombasthenia cases are reported in middle east including individuals of Palestinian, Israel Iran, Iraq, Saudi Arabia,India, Jordan and France. while in these ethnic groups consanguineous marriages is more prevalent [6]
Sex
- Women are slightly more affected by Glanzmann's thrombasthenia than men. The female to male ratio is approximately 1.38 to 1.
References
- ↑ Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.
- ↑ 2.0 2.1 Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F (2004). "Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran". Am J Hematol. 77 (2): 198–9. doi:10.1002/ajh.20159. PMID 15389911.
- ↑ Coller BS, Seligsohn U, Zivelin A, Zwang E, Lusky A, Modan M (April 1986). "Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection". Br. J. Haematol. 62 (4): 723–35. PMID 2938617.
- ↑ Jacquelin B, Tuleja E, Kunicki TJ, Nurden P, Nurden AT (March 2003). "Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3". J. Thromb. Haemost. 1 (3): 573–5. PMID 12871468.
- ↑ Reichert N, Seligsohn U, Ramot B (December 1975). "Clinical and genetic aspects of Glanzmann's thrombasthenia in Israel: report of 22 cases". Thromb Diath Haemorrh. 34 (3): 806–20. PMID 1239828.
- ↑ Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.